View : 14 Download: 0

Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL)

Title
Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL)
Authors
Jung S.-H.Lee J.-J.Kim W.S.Lee W.-S.Do Y.R.Oh S.Y.Kim M.K.Mun Y.-C.Shin H.-J.Kwak J.-Y.Kang H.J.Won J.H.Kwon J.H.Park E.Suh C.Yang D.-H.
Ewha Authors
문영철
SCOPUS Author ID
문영철scopus
Issue Date
2015
Journal Title
European Journal of Haematology
ISSN
0902-4441JCR Link
Citation
vol. 94, no. 6, pp. 504 - 510
Keywords
Diffuse large B-cell lymphomaElderlyRituximab consolidation
Publisher
Blackwell Publishing Ltd
Indexed
SCI; SCIE; SCOPUS WOS scopus
Abstract
This study aimed to determine the objective response, toxicity, and clinical outcome of weekly rituximab consolidation after four cycles of R-CHOP21 in very elderly patients with DLBCL. A prospective, multi-institutional phase II trial was conducted on patients with previously untreated CD20+ DLBCL who were older than 70 yr. Patients were treated with four cycles of R-CHOP21 followed by weekly consolidation with rituximab (375mg/m2, four times infusion) (NCT01181999). We also compared the clinical outcomes with an historical case-matched control group treated conventionally with six cycles of R-CHOP21. A total of 51 patients with newly diagnosed DLBCL were enrolled at 15 institutes between June 2010 and September 2013. The median age was 76 yr (range: 70-89). Forty-one of the 51 patients completed the planned rituximab consolidation (R-consolidation). The overall response rate was 78.4%, comprising 74.5% with a complete response and 3.9% with a partial response. After a median follow-up of 20.3 months, 2-yr progression-free survival and overall survival were 63.9% and 68.7%, respectively. No serious toxicities were reported during rituximab consolidation. Weekly rituximab consolidation following four cycles of R-CHOP21 resulted in an acceptable response with high tolerability and could be a good compromise between efficacy and safety for elderly patients with DLBCL. © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
DOI
10.1111/ejh.12459
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE